logo

For the Inventor, By the Inventor

Morristown, NJ, United States of America

Marc A Labroli

This inventor holds 19 USPTO granted patents and 7 published patent applications and 10 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Merck Sharp + Dohme Corp., Schering Corporation, Merck Sharp & Dohme LLC. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marc A Labroli. Retrieved from https://idiyas.com/inventor/marc-a-labroli

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 19 

% Patents Active = 94.7

 

Average Co-Inventor Count = 8.2

ph-index = 6

Forward Citations = 166(Granted Patents)


Location History:

  • Morrestown, NJ (US) (2012)
  • Mount Laurel, NJ (US) (2002 - 2013)
  • Moorestown, NJ (US) (2013 - 2022)
  • West Point, PA (US) (2021 - 2023)

Company Filing History:

goldMedal10 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal5 out of 1,829 
 
Schering Corporation
 patents
bronzeMedal3 out of 73 
 
Merck Sharp & Dohme LLC
 patents
4. 1 out of 3 
 
Schering Coporation
 patents

Years Active: 2002-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
HIV Integrase Inhibitors
Taro Inhibitors
Cyclin Dependent Kinase Inhibitors
Pyridyl Compounds
Heterocyclic Compounds
Oxazolidinones
Piperazine Derivatives
Protein Kinase Inhibitors
Cell Cycle Checkpoint Modulators
Thiazole Derivatives
Anilinopiperazine Derivatives
Pyrazolopyrimidines
19 patents (USPTO):Explore Patents
1. 12753187 - Amido-substituted pyridyl compounds and methods of use thereof for the treatment of herpesviruses (2026-10-06),
2. 12605369 - Amido-substituted heterocyclic compounds and methods of use thereof for the treatment of herpes viruses (2026-04-21),
3. 12497405 - Bicyclic heterocycle compounds methods of use thereof for the treatment of herpes viruses (2025-12-16),
4. 11752128 - Benzimidazoles and indoles as taro inhibitors (2023-09-12),
5. 11738010 - Oxazolidinones as TarO inhibitors (2023-08-29),
6. 11413292 - Tricyclic heterocycle compounds useful as HIV integrase inhibitors (2022-08-16),
7. 11141410 - Oxazolidinones as taro inhibitors (2021-10-12),
8. 11141403 - Benzimidazoles and indoles as taro inhibitors (2021-10-12),
9. 9206142 - Anilinopiperazine derivatives and methods of use thereof (2015-12-08),
10. 8603998 - Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors (2013-12-10),
11. 8586576 - Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors (2013-11-19),
12. 8580782 - Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors (2013-11-12),
13. 8476278 - Thiazole Derivatives as protein kinase inhibitors (2013-07-02),
14. 8114879 - Piperazine derivatives useful as CCR5 antagonists (2012-02-14),
15. 7605155 - Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors (2009-10-20),

Title: The Innovative Journey of Marc A. Labroli

Introduction: Marc A. Labroli, a talented inventor hailing from Morrestown, NJ, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents: Marc A. Labroli holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and creativity.

Career Highlights: Throughout his illustrious career, Marc A. Labroli has worked with top research institutions and leading tech companies, where he has spearheaded projects that have revolutionized various industries.

Collaborations: Marc A. Labroli is known for his collaborative spirit, having partnered with renowned inventors, patent attorneys, and companies to bring his ideas to life and make a lasting impact on the world.

Conclusion: Marc A. Labroli's passion for innovation and his relentless pursuit of excellence continue to inspire aspiring inventors and shape the future of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…